Drug intelligence / Profile preview

sudo-286

Development stage: Unknown
Lead developer: Sudo Biosciences
Modality: Small Molecules
Administration: Topical

Overview

SUDO-286 is a highly potent, selective, and potential first-in-class topical tyrosine kinase 2 (TYK2) inhibitor developed for the treatment of psoriasis and other immune-mediated dermatologic diseases. It acts by selectively inhibiting tyrosine kinase 2 (TYK2), a key mediator in cytokine signaling pathways involved in immune responses. The drug is being evaluated in two Phase 1 clinical trials as a topical therapy for psoriasis and related conditions. SUDO-286 is designed to provide targeted treatment with minimal off-target effects due to its high selectivity for TYK2.

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on sudo-286.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sudo-286.

Explore the full profile